TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA

Friday, April 21, 2023

PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash University’s upcoming Phase 2 Clinical Trial.

“Australia is rapidly becoming one of the most exciting locations for MDMA research anywhere in the world. I’m sure that the evidence gathered by Prof. Liknaitzky and the team at Monash University will add valuable data to this growing body of research,” said Nick Kadysh, PharmAla’s CEO. “With this supply agreement, PharmAla continues to establish itself as the premier supplier of choice for clinical MDMA researchers in Australia and globally. The Monash team is world-class, and we’re excited to supply them.”

Dr. Liknaitzky is a globally recognized leader in Psychedelics research, as well as Psychedelic-Assisted Psychotherapy training. He is also the co-founder and Chief Scientific Officer of a series of Psychedelic clinics, the first of which is set to open in Melbourne in 2023.

This is the fourth major Clinical Trial to select PharmAla as their MDMA supplier in Australia. PharmAla is the first publicly-traded company to manufacture GMP MDMA, and the first company to make available to researchers two GMP Psychedelic APIs. PharmAla’s LaNeo MDMA is slated to be delivered to Monash university in summer 2023.

 

Source: globenewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit